The effect of isotretinoin in six patients with cutaneous T-cell lymphoma

Published on Thursday, 27 June 2013


Oral retinoids are effective in the treatment of patients with a variety of malignant and nonmalignant skin disorders, including mycosis fungoides.

We treated six patients with cutaneous T-cell lymphomas with isotretinoin 1 to 2 mg/kg/d.

All patients experienced symptomatic relief (fading of skin lesions and disappearance of pruritus) within two to eight weeks of starting the drug therapy; pretreatment and posttreatment biopsy specimens were unchanged. Adverse effects were minor and primarily consisted of drying of the mucous membranes.

We conclude that isotretinoin is a well-tolerated, easily administered drug that provides good palliation of symptoms and signs associated with cutaneous T-cell lymphoma in patients who are unable or unwilling to comply with standard therapy.


About this publication.